Capricor shares drop after FDA issues complete response letter for lead DMD therapy

6 hours ago 1

Healthcare
On the Move

Capricor Therapeutics (NASDAQ:CAPR) shares fell Friday after the company announced it received a complete response letter from the U.S. Food and Drug Administration for its Biologics License Application for Deramiocel, its lead cell therapy candidate for treating cardiomyopathy in Duchenne muscular

Recommended For You

More Trending News

Read Entire Article

Capricor shares drop after FDA issues complete response letter for lead DMD therapy

Recommended For You

More Trending News

Related

Wall Street sees 35% Canada tariff as just a negotiation tac...

Tech Voices: Intel's robotics spinout, Goldman's AI coder, T...

Freeport-McMoRan downgraded at UBS after popping from copper...

Levi Strauss' Q2 results should 'relieve investor doubts' --...

SA analyst upgrades/downgrades: CVX, TLRY, LULU, REGN

15 breakout winners in 2025’s worst-performing S&P sector

The Rise of the Everyday Millionaire, or the EMILLI

Franklin Street Properties declares $0.01 dividend

Casino stocks trade lower after state gaming revenue reports...

Coinbase acquires leadership team of DeFi project Opyn Marke...

Albemarle cut to Sell at UBS, seeing continued lithium glut

Pershing Square CEO Bill Ackman made his professional tennis...

Robinhood faces Florida AG probe for allegedly misrepresenti...

Market Voices: Canadian tariffs, OMB eyes Powell probe, Hasb...

GameStop is auctioning off the stapler that broke Nintendo S...

Top Seeking Alpha tech sector Quant picks ahead of Q2 earnin...

SA Asks: What lies ahead for chip tech provider Wolfspeed?

Box office collection for Gunn's Superman to soar above $200...

Lumentum, Coherent, Fabrinet to benefit from growing optical...

As tech CEOs predict AI will replace humans in just 5 years,...

Trending

Popular

TechCrunch Mobility: The state of EV sales and Rivian secure...

Castelion raises $350M Series B to scale hypersonic missile ...